Copyright
©The Author(s) 2015.
World J Diabetes. Sep 10, 2015; 6(11): 1179-1185
Published online Sep 10, 2015. doi: 10.4239/wjd.v6.i11.1179
Published online Sep 10, 2015. doi: 10.4239/wjd.v6.i11.1179
Figure 1 Schematic representation of different receptor signaling pathways in type 2 diabetes mellitus which can be targeted by new chemical entity.
PKC: Protein kinase C; Akt: Also known as protein kinase B (PKB); GSK3: Glycogen synthase kinase 3; mTOR: Mammalian target of rapamycin; FOXO: Forkhead box subgroup O; PTP-1b: Protein tyrosine phosphatase-1b; GLUT4: Glucose transporter Subtype 4; PI3K: Phosphoinositide 3 kinase; AMPK: AMP activated protein kinase.
- Citation: De B, Bhandari K, Chakravorty N, Mukherjee R, Gundamaraju R, Singla RK, Katakam P, Adiki SK, Ghosh B, Mitra A. Computational pharmacokinetics and in vitro-in vivo correlation of anti-diabetic synergistic phyto-composite blend. World J Diabetes 2015; 6(11): 1179-1185
- URL: https://www.wjgnet.com/1948-9358/full/v6/i11/1179.htm
- DOI: https://dx.doi.org/10.4239/wjd.v6.i11.1179